AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

Search

Main Street Capital Corp

Închisă

SectorFinanțe

63.65 -0.78

Rezumat

Modificarea prețului

24h

Curent

Minim

62.75

Maxim

64.12

Indicatori cheie

By Trading Economics

Venit

-145M

30M

Vânzări

-17M

171M

P/E

Medie Sector

10.932

25.916

Randament dividend

4.51

Marjă de profit

17.309

Angajați

104

EBITDA

-82M

123M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-10.92% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.51%

3.70%

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

975M

5.7B

Deschiderea anterioară

64.43

Închiderea anterioară

63.65

Sentimentul știrilor

By Acuity

58%

42%

452 / 536 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Main Street Capital Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

Main Street Capital Corp Așteptări

Obiectiv de preț

By TipRanks

-10.92% jos

Prognoză pe 12 luni

Medie 57 USD  -10.92%

Maxim 60 USD

Minim 53 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMain Street Capital Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

0

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

52.6034 / 54.64Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

452 / 536 Clasament în Finanțe

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Main Street Capital Corp

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations, and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies ranging between $5 million and $125 million in equity investment with annual revenues between $10 million and $150 million and EBITDA in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $150 million per transaction in debt investment value but holds the ability to lead debt financings up to $250 million and invests between $10 million and $150 million in credit solutions with EBITDA in the range of $5 million and $75 million for credit solutions. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minori